Search Results
Your search for early matches 10012 pages
Showing 1701 - 1750MRI-Guided Ultrasound Focal Therapy May Delay or Avoid Prostatectomy or Radiotherapy in Patients With Intermediate-Risk Prostate Cancer
MRI-guided focused ultrasound focal therapy produced “a high degree of success” and “a low rate of genitourinary adverse events” when used to treat select patients with intermediate-grade prostate cancer, Behfar Ehdaie, MD, MPH, and colleagues reported in The Lancet Oncology.1 Dr. Ehdaie is...
Long-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-up
Radiotherapy to the prostate in addition to standard treatment may improve survival for some men with advanced prostate cancer without detriment to quality of life, long-term study results from the STAMPEDE trial confirmed. These findings were published by Chris C. Parker, MD, and colleagues in...
Adding CT to X-Ray for Follow-up of Completely Resected NSCLC
In a French phase III trial (IFCT-0302) reported in The Lancet Oncology, Westeel et al found that a strategy including computed tomography (CT) and x-ray vs x-ray alone did not improve overall survival when used in the follow-up of patients with completely resected non–small cell lung cancer...
New Guideline Updates Address Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations
Two ASCO guideline updates provide new evidence-based recommendations for the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations.1,2 Among several other updates, these new guidelines add the ALK and ROS1 inhibitor lorlatinib and the PD-L1 immune...
Expert Point of View: Javier Cortés, MD, PhD
The invited discussant of the updated APHINITY data was Javier Cortés, MD, PhD, Head of the International Breast Cancer Center in Barcelona. “I think we clearly learned two things from the data. One is that estrogen receptor positivity does not matter in terms of benefit from the addition of...
Racial Trends in Advanced Cervical Cancer in the United States
The steepest annual rise in new cases of advanced cervical cancer in the United States from 2001 to 2018 was among White patients, who were significantly less likely to receive the preventive human papillomavirus (HPV) vaccine or to be screened for the disease, according to research published by...
APHINITY Trial in Patients With HER2-Positive Early Breast Cancer: Update at 8 Years
Updated results from the adjuvant APHINITY trial in HER2-positive early breast cancer, now with a median follow-up of 8.4 years, confirmed the benefit of adding pertuzumab to trastuzumab plus chemotherapy in preventing invasive disease recurrences, but as yet no statistically significant overall...
Study Evaluates UV Protective Behaviors in American Indian and Alaskan Native Populations
Ultraviolet (UV) protection from the sun and avoiding indoor tanning play important roles in reducing a person’s risk for skin cancer, the most common cancer in the United States and one of the most preventable. A recent article published by Yang et al in the Journal of the American Academy of...
Snapshots of Studies of Interest Presented at ASCO 2022
The 2022 ASCO Annual Meeting was filled with important science, engaging data, and several practice-changing abstracts, many of which have been covered in detail on other pages or in earlier issues of The ASCO Post. There were numerous high-impact studies and attendees, whether present at the...
Impact of the Dobbs v Jackson Women’s Health Organization Ruling on Patients With Cancer
As a nonpartisan organization, the American Cancer Society has an overarching goal to improve the lives of patients with cancer and their families. We believe all individuals should have an equitable opportunity to prevent, find, detect, and survive cancer, irrespective of geography. The June 24...
Is Science Getting Closer to Preventing Multiple Myeloma?
About 3 years ago, researchers from Dana-Farber Cancer Institute launched PROMISE (Predicting Progression of Developing Myeloma in a High-Risk Screen Population; ClinicalTrials.gov identifier NCT03689595), a large, ambitious screening study to identify individuals at high risk of developing...
Real-World Evidence Confirms Survival Benefit of Durvalumab in Locally Advanced Non–Small Cell Lung Cancer
In locally advanced non–small cell lung cancer (NSCLC), immunotherapy consolidation with the PD-L1 inhibitor durvalumab improved overall survival in the PACIFIC trial,1 thus leading to its use after chemoradiotherapy as a standard of care. Real-world evidence of durvalumab’s effect on overall and...
Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, de Vries et al developed risk models for predicting the development of coronary heart disease and heart failure in patients treated for Hodgkin lymphoma. Study Details The prediction models were developed in a Dutch cohort of 1,433 5-year...
Is Advance Care Planning of Any Value?
An article in The New York Times earlier this year crystallized the dilemma facing health-care providers when they are presented with a patient in a life-threatening situation: Should they rely on advance care directives written years prior to the current medical situation to accurately determine...
Low-Dose Decitabine and Azacitidine in Lower-Risk MDS
As reported in NEJM Evidence by Sasaki et al, extended follow-up of a phase II trial showed good outcomes with low doses of the hypomethylating agents decitabine and azacitidine in previously untreated patients with lower-risk myelodysplastic syndromes (MDS). Study Details The study included 113...
RATIONALE-306: Survival Benefit Attained With Tislelizumab in Advanced Esophageal Cancer
In patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of the checkpoint inhibitor tislelizumab to first-line chemotherapy significantly improved overall survival vs chemotherapy alone, according to an interim analysis of the global phase III RATIONALE-306 trial....
Study Shows Germline Testing May Be Warranted for All Patients With Lung Cancer
Germline testing may be warranted for all patients with lung cancer, according to research presented by Sorscher et al during the August ASCO Plenary Series Program (Abstract 388570). The retrospective review of nearly 8,000 patients with lung cancer undergoing germline testing found that 14.9% had ...
A Surgical Oncologist From Afghanistan Discusses the Challenges of Delivering Cancer Care in a War-Torn Nation
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Ahmad Bashir Barekzai, MD, FACS, Consultant Surgical Oncologist at Ali Abad Teaching Hospital, an affiliated hospital to Kabul University of Medical Science, Kabul,...
Breast Induration Risk With Partial- vs Whole-Breast Irradiation After Breast-Conserving Surgery for Node-Negative Early Disease
As reported in the Journal of Clinical Oncology by Offersen et al, the phase III Danish Breast Cancer Group Partial Breast Irradiation Trial showed that partial-breast irradiation was noninferior to whole-breast irradiation in terms of the risk for breast induration in women aged ≥ 60 years...
Study Investigates Incidence, Timing, and Survival of Patients With Second Primary Lung Cancer
Using data from the National Lung Screening Trial (NLST), researchers found that the incidence of second primary lung cancer was approximately 4% among the entire cohort of patients with lung cancer and was as high as 8% among patients undergoing surgery for stage IA disease. The research was...
NELSON Trial Protocol May Be More Sensitive Than NLST, May Increase Benefits of Lung Cancer Screening
The protocol used to screen and detect lung cancer in the NELSON trial may be more sensitive than the protocol used in the National Lung Cancer Screening Trial (NLST), particularly for early-stage cancers, according to research reported by de Nijs et al at the International Association for the...
Time to Initiation of Adjuvant Endocrine Therapy and Likelihood of Adherence in Medicaid-Insured Women With Breast Cancer
In a population-based retrospective cohort study reported in JAMA Network Open, Sood et al found that longer time to adjuvant endocrine therapy initiation in Medicaid-insured women with breast cancer was associated with a reduced likelihood of short- and long-term adherence to treatment. As stated...
Disparities in the Diagnosis of Lung Cancer Among Younger vs Older Adults
Younger patients with lung cancer are significantly more likely than older patients to be diagnosed with later stages of disease, illustrating the need to develop strategies to increase the early detection of lung cancer among younger patients who are currently ineligible for lung cancer screening. ...
Dana-Farber’s Irene Ghobrial, MD, Selected as William Dameshek Prize Winner
Irene Ghobrial, MD, Director of the Clinical Investigator Research Program at Dana-Farber Cancer Institute, Boston, has received the William Dameshek Prize. This award is given annually by the American Society of Hematology (ASH) to an individual younger than age 50 who has made outstanding...
Radiologist Claudia Henschke, PhD, MD, of Icahn School of Medicine, Receives the 37th Annual Alton Ochsner Award
Ochsner Health has announced the recipient of the 37th Annual Alton Ochsner Award Relating Smoking and Disease: Claudia Henschke, PhD, MD. She is Director, Early Lung and Cardiac Action Program (ELCAP) and Professor of Radiology at the Icahn School of Medicine at Mount Sinai, New York. This...
His Grandmother’s Death Inspires a Career in Oncology for Manmeet S. Ahluwalia, MD, MBA
In this installment of Living a Full Life, Guest Editor Jame Abraham, MD, spoke with Manmeet S. Ahluwalia, MD, MBA, Deputy Director, Chief Scientific Officer, and Chief of Solid Tumor Medical Oncology at Miami Cancer Institute, where his research focuses on the development of new therapies for...
Increased Utilization of SBRT Has Decreased Treatment Disparities for Early-Stage NSCLC
The use of stereotactic body radiotherapy (SBRT) for patients with non–small cell lung cancer (NSCLC) can reduce treatment disparities between White and Black patients, according to research presented by Ganesh et al at the International Association for the Study of Lung Cancer (IASLC) World...
ASCO Releases First Comprehensive Evidence-Based Guidelines for Metastatic Clear Cell Renal Cell Carcinoma
ASCO has released the first comprehensive set of guidelines for the management of metastatic clear cell renal cell carcinoma (RCC).1 The guidelines are subdivided into six main sections: diagnosis, the role of cytoreductive nephrectomy, first-line systemic treatment, second- or later-line systemic...
An Early Encounter With Cancer Sets a Path to a Career in Oncology Research
To shed some light on the importance of caring for the whole patient and his or her caregiver, as well as the role of cellular aging and oncogenesis, The ASCO Post recently spoke with Kaumudi Bhawe, PhD, a clinical scientist with Cancer Commons in Mountain View, California. Dr. Bhawe has more than ...
Cancer Knows No Borders
This is a critical time for cancer research and cancer care across the world, and the cancer community has clearly highlighted the need for greater and more equitable international collaboration. Addressing the global cancer challenge is a significant undertaking, and it has become more urgent as ...
Long-Term Outcomes With Adjuvant Goserelin and Tamoxifen in Premenopausal Estrogen Receptor–Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Johansson et al, 20-year follow-up of the Stockholm trial (STO-5) has shown long-term reduction in the risk of distant recurrence with 2 years of adjuvant endocrine therapy with goserelin and tamoxifen vs no endocrine therapy in premenopausal women ...
Media Emphasis on Urinary Symptoms May Delay Diagnosis of Early Prostate Cancer
According to Cancer Research UK, over 52,000 men are diagnosed with prostate cancer each year in the UK, and there are more than 12,000 deaths. Over three-quarters (78%) of men diagnosed with the disease survive for over 10 years, but this proportion has barely changed over the past decade in the...
Older Age and Smoking Are the Most Important Risk Factors for Developing Any Cancer, Study Shows
A new large study led by researchers at the American Cancer Society (ACS) shows older age and smoking are the two most important risk factors associated with a relative and absolute 5-year risk of developing any cancer. The findings also demonstrate that in addition to age and smoking history,...
Study Suggests HPV Vaccination Alongside Local Excision of Cervical Lesions May Reduce Risk of Recurrence
Giving women the human papillomavirus (HPV) vaccine around the time they have surgery for precancerous cervical lesions might lead to a reduction in the risk of lesions returning as well as other HPV-related diseases, suggests a study published by Kechagias et al in The BMJ. The researchers...
Study Could Lead to Better Education and Treatment of Sexual Health for Patients With Breast Cancer
A study released by the University of Colorado Cancer Center showed that more than 70% of patients with breast cancer have reported changes that affect their sexual health during and beyond treatment. The study was published by Huynh et al in the Annals of Surgical Oncology. Study Background “More...
New Study Shows Options for Older Patients With Liver Cancer
Physicians and researchers from UK HealthCare's Transplant Center and the University of Kentucky Markey Cancer Center conducted a study of patients over age 70 with hepatocellular carcinoma to examine how the outcomes of ablative treatments compare to liver transplants. The findings were published...
Survey Reveals That Most Americans Are Not Concerned About Getting Lung Cancer
A recent survey shows that only 40% of Americans are concerned that they might get lung cancer, and only about one in five have talked to their doctor about their risk for the disease, despite lung cancer being the leading cause of cancer deaths in the United States. The 2022 Lung Health Barometer, ...
Oral Paclitaxel Plus P-Glycoprotein Pump Inhibitor Encequidar vs Intravenous Paclitaxel in Metastatic Breast Cancer
In a Latin American phase III trial reported in the Journal of Clinical Oncology, Hope S. Rugo, MD, and colleagues found that oral paclitaxel with the P-glycoprotein pump inhibitor encequidar produced a higher response rate and trends toward better survival outcomes vs intravenous (IV) paclitaxel...
Brentuximab Vedotin Plus AVD vs ABVD for the First-Line Treatment of Early-Stage Unfavorable-Risk Hodgkin Lymphoma
In a European phase II trial (BREACH) reported in the Journal of Clinical Oncology, Fornecker et al found that brentuximab vedotin (BV) plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) improved the rate of positron-emission tomography (PET)-negative status after two cycles of treatment vs...
Noted Oncology Surgeon Kevin Billingsley, MD, MBA, FACS, Uses Life Experiences to Mold His Leadership Philosophy
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kevin Billingsley, MD, MBA, FACS, Chief Medical Officer of the Smilow Cancer Hospital and Yale Cancer Center. Although interracial marriage is common in the United States...
Early Research Finds Link May Connect Cell-Signaling Pathway to Development of Esophageal Cancers, Barrett’s Esophagus
A team of researchers believe they have identified a cell-signaling pathway responsible for the development of esophageal adenocarcinomas, an aggressive type of esophageal cancer that has gradually become more common, even in younger people. Research published by Venkitachalam et al in...
Risk Stratification and Treatment Implications for Patients With Early-Stage Melanoma and Sentinel Node Metastasis
In a study reported in the Journal of Clinical Oncology, Moncrieff et al found that patients with stage IIIA melanoma (per American Joint Committee on Cancer [AJCC], 8th edition) with sentinel node metastatic tumor deposits ≥ 0.3 mm are at higher risk of disease progression vs those with smaller...
Researchers Find Potential Link Between Genetic Mutations and Treatment Resistance in Patients With Relapsed or Refractory Multiple Myeloma
Researchers studying the molecular landscape of over 500 patients with relapsed or refractory multiple myeloma discovered a prevalence of activated key oncogenic pathways in these patients—much more than previously thought. Upward of 45% to 65% of NF-κB and RAS/MAPK pathways each had alterations....
ASCO Guideline Update Supports New Second- and Third-Line Treatments for HER2-Positive Breast Cancer
ASCO has issued a new practice guideline update on the use of systemic therapy for HER2-positive breast cancer, just 4 years after the previous practice guideline update was released in 2018.1,2 This latest update reviews results from multiple clinical trials published between 2016 and 2021 that...
Study Finds Radiation Therapy May Be Safely Omitted for Some Older Patients With Luminal A Breast Cancer
For some patients aged 55 or older with early-stage, low-risk breast cancer, endocrine therapy following breast-conserving surgery may be sufficient without the need for postoperative radiation therapy, according to the results of the prospective LUMINA trial, reported at the 2022 ASCO Annual...
Changing the Natural History of ER-Positive, HER2-Negative Breast Cancer With the Introduction of CDK4/6 Inhibition
It has been 14 years since a collaboration between the University of California, Los Angeles (UCLA) and Pfizer identified a unique role for cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in estrogen receptor (ER)-positive human cell line models and demonstrated that these agents act...
Study Reports Time-Limited Venetoclax-Based Regimens of Benefit in Front-Line Treatment of CLL
Time-limited venetoclax-based regimens provide deeper and more durable remissions than chemoimmunotherapy combinations in patients with previously untreated chronic lymphocytic leukemia (CLL), regardless of patients’ fitness, according to late-breaking data presented during the European Hematology...
Adjuvant Everolimus Narrowly Misses Statistical Significance in RCC, Except for Very High–Risk Patients
In the phase III EVEREST trial, adjuvant everolimus improved median recurrence-free survival in patients with resected renal cell carcinoma (RCC), but this finding failed to be statistically significant in the total study population of 1,499 patients, according to a prespecified boundary. However,...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Two Early-Career Cancer Researchers From Africa Aim to Make a Difference and Never Give Up
In countries with a high income, research in oncology is sponsored by funding agencies and industry, which has meaningfully improved survival outcomes of patients with cancer. In contrast, the African continent is disadvantaged in all aspects of human development, particularly in the fields of...
